Patents Examined by Bahar Schmidtmann
-
Patent number: 7960354Abstract: Synergistic pesticidal mixtures are provided.Type: GrantFiled: May 1, 2008Date of Patent: June 14, 2011Assignee: Dow AgroSciences LLCInventors: Jim X. Huang, Jonathan M. Babcock, Thomas Meade, Marc Farrow
-
Patent number: 7960352Abstract: The present invention relates to an Androsace umbellata Merr. extract having anticancer activity and a triterpene saponin compound isolated therefrom, more particularly to an Androsace umbellata (Lour.) Merr. extract, triterpene saponin compounds isolated therefrom, saxifragifolin B and saxifragifolin D, which inhibit the growth of cancer cells and induce apoptosis of cancer cells, and thus are useful for preparing a composition for preventing and treating cancers and a method of isolating a triterpene saponin compound from an Androsace umbellata Merr. extract.Type: GrantFiled: September 14, 2006Date of Patent: June 14, 2011Assignee: Sungkyunkwan University Foundation for Corporate CollaborationInventors: Ok Pyo Zee, Se Chan Kang, Jon g Hwan Kwak, Joa Sub Oh, Han Choi, Jong Phil Bak, Chang Min Lee, Yong Joon Cheong
-
Patent number: 7943764Abstract: A method for isolating sulphated glycosaminoglycans washes a mechanically cleaned tissue, exposes tissue in a solution of 0.1M phosphate pH 5.8-6.0 buffer heated to a temperature of 65° C. for 30 minutes, overcooks the tissue in activated 0.1-0.4% papain at 65° C. for 6-24 hours, cools the papain digest to 4° C., removes fats and undigested tissue residues, selectively isolates the sulphated glycosaminoglycans for 4-10 hours on a solid carrier, obtained from bone tissue collagen with particle sizes ranging from 0-01 to 0.35 cm3, washes the carrier with 0.05-0.1 N-hydrochloric acid, degreases and eluates the carrier with a solution of 0.6-0.15 N-mineral salt in 0.8 N-acetic acid or in 0-01-0-025 N-alkali liquor, precipitates the sulphated glycosaminoglycans with ethanol, centrifuges with 1500 r.p.m. for 15 minutes at a temperature of 4° C., washes the precipitate with ethanol or acetone, and dries and sterilizes the precipitate.Type: GrantFiled: October 27, 2005Date of Patent: May 17, 2011Inventor: Andrey Fedorovich Panasyuk
-
Patent number: 7923541Abstract: A process for recovering Rebaudioside A from Stevia rebaudiana Bertoni plants is provided and includes the steps of sequentially extracting plant material with a first solvent to obtain a first extract, filtering the first extract and passing the first extract through a polar resin to obtain a filtrate, and purifying the filtrate to obtain a crystalline-containing material. With further purification, a product containing over 99% Rebaudioside A is obtained. The present invention is also directed toward a method of purifying stevia glycosides to obtain purified Rebaudioside A. In one embodiment, the method includes silica gel column chromatography using an solvent comprising ethyl acetate and ethanol.Type: GrantFiled: December 17, 2007Date of Patent: April 12, 2011Assignee: Chengdu Wagott Pharmaceutical Co., Ltd.Inventors: Mingfu Yang, Jun Hua, Ling Qin
-
Patent number: 7923434Abstract: The invention concerns pharmaceutical compositions comprising as active compound at least one compound of general formula (A), wherein: M represents a metal atom, and their uses in particular for preventing or treating pathologies associated with an excess activity of glutathion reductase and/or thioredoxin reductase.Type: GrantFiled: July 29, 2005Date of Patent: April 12, 2011Assignee: Centre National de la Recherche ScientifiqueInventors: Elisabeth Davioud-Charvet, Katja Becker-Brandenburg, Valérie Deborde, Régis Reau, R. Heiner Schirmer, Christel Herold-Mende
-
Patent number: 7915228Abstract: The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the pharmaceutical composition.Type: GrantFiled: June 2, 2008Date of Patent: March 29, 2011Assignee: Tioga Pharmaceuticals, Inc.Inventors: Matthias Wiesner, Christoph Seyfried
-
Patent number: 7884203Abstract: The invention discloses a method for improving the yield of sucralose, including reacting sucrose to produce sucrose-6-acetate in the existence of an azo reagent as a catalyst and acetic acid as an acylating agent in a proper solvent; then reacting sucrose-6-acetate with a proper chlorinating agent to produce sucralose-6-acetate in a non-proton polar solvent with TCA as a catalyst; and at last, alcoholyzing sucralose-6-acetate in KOH/methanol to obtain sucralose.Type: GrantFiled: June 28, 2006Date of Patent: February 8, 2011Assignee: JK Sucralose Inc.Inventors: Fei Wang, Haibing He, Xin Yang, Yongzhu Yu, Zhisong Fan
-
Patent number: 7884195Abstract: The present invention provides a method of extracting ginsenoside Rg2, which is applied to mass production. The method of the present invention employs gradient salting-out instead of conventional silica gel chromatography, and therefore enables convenient performance and mass production of ginsenoside Rg2. Provided are also a pharmaceutical composition comprising ginsenoside Rg2 as an active ingredient, and prophylactic and therapeutic agents for preventing and treating dementia, depression, peripheral circulation disorder and related diseases, utilizing the pharmaceutical composition.Type: GrantFiled: April 26, 2005Date of Patent: February 8, 2011Inventor: Long Yun Li
-
Patent number: 7847092Abstract: The present invention relates to a method for preparation of organofluoro compounds containing radioactive isotope fluorine-18. More particularly, the present invention relates to a method for preparation of primary or secondary organofluoro compound by reacting fluorine salt containing radioactive isotope fluorine-18 with primary or secondary alkyl halide or primary or secondary alkyl sulfonate in the presence of alcohol of Chemical Formula 1 as a solvent to obtain high yield of organofluoro compound. Synthesis reaction according to the present invention may be carried out under mild condition to give high yield of the organofluoro compounds and the reaction time is decreased, and thereby is suitable for the mass production of the organofluoro compounds.Type: GrantFiled: December 9, 2005Date of Patent: December 7, 2010Assignees: FutureChem Co., Ltd., The Asan FoundationInventors: Dae Hyuk Moon, Dae Yoon Chi, Dong Wook Kim, Seung Jun Oh, Jin-sook Ryu
-
Patent number: 7846903Abstract: A cubic liquid crystal composition comprising at least one amphiphilic compound having the following general formula (1) and having an IV/OV value of 0.65 to 0.95, and water or an aqueous medium: wherein R represents a hydrophilic group; X and Y each independently represent a hydrogen atom or together form an oxygen atom; n is an integer of 0 to 4; and m is an integer of 0 to 3.Type: GrantFiled: October 19, 2005Date of Patent: December 7, 2010Assignees: National Institute of Advanced Industrial Science and Technology, Kuraray Co., Ltd., Cytopathfinder, Inc.Inventors: Masakatsu Hato, Yoshiji Fujita, Toshitaka Ota, Masahisa Tanomura, Manzo Shiono
-
Patent number: 7838643Abstract: The present invention relates to novel quaternized polymers, especially of chitin/chitosan type, and to carbohydrate polymers carrying quaternized ammonium groups, especially piperazinium groups. Such polymers are characterized i.a. by improved solubility characteristics.Type: GrantFiled: August 31, 2006Date of Patent: November 23, 2010Assignee: Archimedes Development LimitedInventors: Jukka Holappa, Tomi Järvinen, Tapio Nevalainen, Jouko Savolainen, Rustam Safin
-
Patent number: 7816400Abstract: This invention provides a method for treating or preventing human atrial arrhythmia (fibrillation) using the leading flavone compound acacetin, and its derivatives and analogues that inhibit the ultra-rapidly-activating delayed rectifier potassium current (IKur or IKsus), transient outward potassium (Ito), and acetylcholine-activated potassium current (IK.ACh).Type: GrantFiled: February 29, 2008Date of Patent: October 19, 2010Assignees: The University of Hong Kong, Shanghai Institute of Materia Medica, Chinese Academy of SciencesInventors: Gui-Rong Li, Chu-Pak Lau, Guo-Wei Qin, Hong-Bing Wang
-
Patent number: 7811549Abstract: Methods are presented that comprise the administration of a pharmaceutical composition comprising adenosine and dipyridamole, as well methods comprising the combined administration of dipyridamole administered as a bolus with adenosine given as an infusion, both at dosages below their respective single agent dosages, for detecting the presence and/or assessing the severity of myocardial ischemia during pharmacologic stress tests. The methods are useful for exploiting the vasodilating abilities of adenosine at doses at which side effects related to adenosine are substantially reduced while optimal coronary artery perfusion is achieved. Also presented are compositions, unit dosage forms, and kits that are useful in performing the methods.Type: GrantFiled: July 2, 2007Date of Patent: October 12, 2010Assignee: Adenobio N.V.Inventor: Philippe Gorny
-
Patent number: 7732426Abstract: The present invention have objects to provide an option of non-reducing saccharide by providing a novel non-reducing saccharide composed of glucose as constituents and to provide a novel enzyme forming the non-reducing saccharide, a method and process for producing the same, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, a composition comprising the non-reducing saccharide, and uses thereof. The present invention solves the above objects by providing an isocyclomaltooligosaccharide(s) having a structure represented by General Formula 1, a novel isocyclomaltooligosaccharide-forming enzyme, a method and process for producing the same, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, a composition comprising the isocyclomaltooligosaccharide(s) or a saccharide composition comprising the same, and uses thereof. Cyclo{?6)-[?-D-Glcp-(1?4)]n-?-D-Glcp-(1?}??General Formula 1 (In General Formula 1, “n” means a number of 4 or 5).Type: GrantFiled: September 26, 2005Date of Patent: June 8, 2010Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Hikaru Watanabe, Tomoyuki Nishimoto, Michio Kubota, Shigeharu Fukuda, Toshio Miyake
-
Patent number: 7714115Abstract: The invention provides a method for the synthesis of an 18F-labelled product comprising deprotected of a protected 18F-labelled compound using a deprotection agent comprising a weak acid and wherein neutralisation and buffering of the deprotected product are carried out by the addition of a neutralisation agent. The deprotected product is buffered in a pH range suitable for subsequent autoclaving and formulation into an injectable radiopharmaceutical.Type: GrantFiled: September 23, 2005Date of Patent: May 11, 2010Assignee: GE Healthcare LimitedInventors: Julian Grigg, Nigel Osborn
-
Patent number: 7696177Abstract: This invention provides cholesterol absorption inhibitors of Formula (I), and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.Type: GrantFiled: June 9, 2006Date of Patent: April 13, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Robert J. DeVita, Greg J. Morriello, Anthony K. Ogawa, Feroze Ujjainwalla
-
Patent number: 7666845Abstract: The invention is directed to compounds of the formula (I) described herein, a pharmaceutically acceptable salt thereof, or a prodrug thereof, and pharmaceutical compositions and methods of treatment.Type: GrantFiled: December 3, 2007Date of Patent: February 23, 2010Assignee: Janssen Pharmaceutica N.V.Inventors: Kevin L. Cook, Heng-Keang Lim, Frank J. Villani, Lorraine Scott, Christian Andrew Baumann
-
Patent number: 7612049Abstract: The inhibition of Chlorophyta growth in water needed to be treated can be accomplished by the addition of about 100 ppm glucosamine. The inhibition of Microcystic aeruginosa and Microcystis flos-aquae growth in water needed to be treated can be accomplished by the addition of about 10 to 50 ppm glucosamine. The addition of glucosamine to water needed to be treated, such as reservoirs, offers an environmentally safe method for inhibiting algae growth.Type: GrantFiled: November 8, 2007Date of Patent: November 3, 2009Assignee: ITEQ CorporationInventor: Chih-Ta Kao